MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion

Su, Xiaomei; Zhang, Ling; Li, Hua; Peng, Cheng; Zhu, Yeping; Liu, Zhen; Zhao, Yu; Xu, Hongyu; Liu, Dong; Gao, Hui; Zhang, Tao

doi:10.3892/ol.2017.5644

Cited by 19 publications

(19 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, previous studies also reported that miR‐134 expression was downregulated in variety of human cancers, such as osteosarcoma , glioma , breast cancer , lung cancer, and colorectal cancer , and gastric cancer . The targeting of miR‐134 expression inhibited the malignant phenotypes of these cancers . Thus, miR‐134 could be a tumor suppressor gene in different human cancers .…”

Section: Discussionmentioning

confidence: 92%

miR‐134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo

et al. 2019

View full text Add to dashboard Cite

miR‐134 has been shown to be associated with angiogenesis and the progression of osteosarcoma. This study further assessed the effects of miR‐134 expression on osteosarcoma cell migration, invasion, and metastasis in vitro and in a nude mouse xenograft model, exploring the underlying molecular events. Luciferase reporter assays revealed that miR‐134 directly targets the 3′‐UTRs of MMP1 and MMP3 to reduce their expression in osteosarcoma cells. In conclusion, overexpression of miR‐134 suppresses osteosarcoma cell invasion and metastasis through the inhibition of MMP1 and MMP3 expression. We propose miR‐134 as an attractive novel therapeutic target for the treatment of osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 92%

miR‐134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This gene mainly functions in signaling pathways involving membrane receptors and cAMP. KRAS has the strongest influence on malignant cancer in the RAS family (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

miR‑202 acts as a potential tumor suppressor in breast cancer

et al. 2018

View full text Add to dashboard Cite

Abstract. Breast cancer affects ~10% of women worldwide and is responsible for ~12% of all cancer-associated mortalities. Breast cancer is more prone to metastasis compared with other types of cancer. Up to 5% of patients with breast cancer present with incurable metastasis and an additional 10-15% of patients develop metastases within 3 years of their initial diagnosis. MicroRNAs (miRNAs) are short RNAs, 21-25 nucleotides in length, that have been shown to significantly affect gene expression. In total >2,000 miRNAs have been identified and specific miRNAs have been revealed to be associated with cancer. In the present study, we observed that the majority of breast cancer specimens collected expressed low levels of miR-202 compared with adjacent tissues and normal cell lines. Mechanistic investigations identified KRAS as a potential target gene of miR-202 and it was demonstrated that miR-202 exerted its tumor-suppressive effects by regulating the expression of KRAS in breast cancer cells. Functional assays revealed that miR-202 significantly reduced cell proliferation, migration and invasion in vitro. In summary, these results indicate the function of miR-202 in breast cancer progression and suggest that its use within breast cancer therapy is promising. IntroductionBreast cancer is one of the most common malignant tumors in women. In many areas, breast cancer is the most common malignancy in females. In China, the incidence of breast cancer is increasing annually. Because the development and progression of breast cancer are complex processes involving many genes, the underlying mechanism of breast cancer remains unclear (1,2).Single-stranded RNAs consisting of 19 to 25 nucleotides are known as microRNAs (miRNAs). These RNAs are regulatory molecules that modulate the expression of functional genes, play an important role in many biological processes, and are expressed in a tissue-and time-specific manner. miRNAs regulate gene expression at the post-transcriptional level mainly via completely complementary or partially complementary binding to the 3' UTR of the target gene, resulting in degradation or translational repression of the target gene (2-4). Studies have shown that a variety of miRNAs are involved in malignant transformation processes, such as malignant proliferation, metastasis and recurrence, and apoptosis inhibition. Studies have reported that miRNA inhibitors can reduce the high miR-21 expression in breast cancer cells, inhibiting proliferation and migration; that miR-373 can promote the metastasis of breast cancer cells; that miR-520 plays a role in promoting the development of breast cancer; and that miR-126 and miR-335 are able to inhibit breast cancer to a certain extent (5-7). Recent studies have demonstrated that miR-202 is associated with several types of cancer, miR-202 has a lower expression in several of cancers, and however, the expression and function of miR-202 have not been investigated in breast cancer (8).KRAS belongs to the RAS family; it is located on the short arm of chromosome 1...

show abstract

“…The expression of miR‐134‐5p has been previously studied in various diseases. For instance, miR‐134 suppresses breast cancer progression by targeting KRAS . miR‐134 can inhibit gastric cancer cell proliferation via targeting GOLPH3 .…”

Section: Discussionmentioning

confidence: 99%

“…miR‐190a‐5p can contribute to diabetic neuropathic pain through targeting SLC17A6 . In addition, miR‐30b attenuates neuropathic pain development via Voltage‐Gated Sodium Channel Nav1.3 …”

Section: Introductionmentioning

confidence: 99%

MiR‐134‐5p attenuates neuropathic pain progression through targeting Twist1

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Neuropathic pain is a kind of chronic pain because of dysfunctions of somatosensory nerve system. Recently, many studies have demonstrated that microRNAs (miRs) play crucial roles in neuropathic pain development. This study was designed to investigate the effects of miR-134-5p on the process of neuropathic pain progression in a rat model established by chronic sciatic nerve injury (CCI). First, we observed that miR-134-5p was significantly decreased in CCI rat models. Overexpression of miR-134-5p strongly alleviated neuropathic pain behaviors including mechanical and thermal hyperalgesia. Meanwhile, inflammatory cytokine expression, such as IL-6, IL-1β and TNF-α in CCI rats were greatly repressed by upregulation of miR-134-5p. Twist1 has been widely regarded as a poor prognosis biomarker in diverse diseases. Here, by using bioinformatic analysis, 3'-untranslated region (UTR) of Twist1 was predicted to be a downstream target of miR-134-5p in our study. Here, we found that overexpression of miR-134-5p was able to suppress Twist1 dramatically. Furthermore, it was exhibited that Twist1 was increased in CCI rats time-dependently and Twist1 was inhibited in vivo. Subsequently, downregulation of Twist1 in CCI rats could depress neuropathic pain progression via inhibiting neuroinflammation. In conclusion, our current study indicated that miR-134-5p may inhibit neuropathic pain development through targeting Twist1. Our findings suggested that miR-134-5p might provide a novel therapeutic target for neuropathic pain.

show abstract

MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion

Cited by 19 publications

References 44 publications

miR‐134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo

miR‐134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo

miR‑202 acts as a potential tumor suppressor in breast cancer

MiR‐134‐5p attenuates neuropathic pain progression through targeting Twist1

Contact Info

Product

Resources

About